Myovant Sciences (NYSE: MYOV), a biopharmaceutical company focused on the innovative treatment of endocrine diseases, has secured flexible financing commitments of up to USD 140 million from NovaQuest Capital Management and Hercules Capital, Inc. The proceeds from both financings will be used to fund the ongoing Phase 3 development of Myovant's lead compound "relugolix".
VISCHER advised Myovant Sciences as Swiss counsel. The VISCHER team includes Dr. Adrian Dörig (Partner, Corporate), Christoph Niederer (Partner, Tax), Sebastian Flückiger (Associate, Corporate), Ruben Masar (Associate, Corporate) and Seraina Tsering (Associate, Corporate ).